The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Predictors of health-related quality of life in newly diagnosed multiple myeloma
Catherine Lecat, MBBS, University College London, London, UK, discusses findings from the RADAR trial evaluating factors associated with health-related quality of life in patients with newly diagnosed multiple myeloma. She highlights anemia, bone lesions, age and higher International Staging System (ISS) stage as independent predictors of poorer quality of life, rather than high-risk cytogenetics or renal impairment, emphasizing the importance of addressing individual functional and supportive care needs. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
